The world's first 2019-nCoV (SARS-CoV-2) CLIA Kits received CE mark

Release Date:2020-03-06

Shenzhen, China, 19 February 2020 - Snibe announced that MAGLUMI® 2019-nCoV (SARS-CoV-2) IgM/IgG kits have got CE marked and are available to come into service. 

Having passed rigorous clinical verification in China, MAGLUMI® 2019-nCoV (SARS-CoV-2) IgM/IgG kits are proven to possess great performance. With the advantage of rapid detection and high specificity, the new SARS-CoV-2 lgG/lgM kits can be tremendously helpful to identify the infected populations and reduce the false-negative cases of nucleic acid assay in suspected COVID-19 patients, which can greatly improve the diagnostic accuracy of COVID-19 in labs and hospitals. 
  
With the increasing number of COVID-19 cases around the world, in order to improve the clinical diagnosis speed and help the fight against of SARS-CoV-2, the first batch of MAGLUMI®  2019-nCoV (SARS-CoV-2) reagent kits have been distributed to several key hospitals in China, Italy and other countries with severe epidemics for cooperation in the past weeks. 

Snibe is always concerned with global public health and security and ready to help governments cope with public health emergencies. We believe that, with all the efforts from the society, we will achieve the victory in the fight against the SARS-CoV-2 very soon.

Advantage & Benefit

● World's Fastest Fully automated CLIA solution (High throughput and sensitivity method).
The World's First CE Marked CLIA Antibody Assay for COVID-19.
Joint Detection Solution (IgG+IgM) for SARS-CoV-2 to ensure high clinical sensitivity
Rapid detection within 30 mins (Analyzer model dependent)
Antibody detection with numerical results using ONLY 10μL sample volume
Inactivated Serum/Plasma samples (56℃,30mins) applicable to ensure operator's safety.
The First COVID-19 Antibody Reagents Supplier with Major Lab Automation connectability (  /   )
High production capacity with advanced automatic production line